Plantar Fasciitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major plantar fasciitis markets are expected to exhibit a CAGR of 17.88% during 2024-2034.
The plantar fasciitis market has been comprehensively analyzed in IMARC's new report titled "Plantar Fasciitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Plantar fasciitis refers to a common condition that involves inflammation and irritation of the plantar fascia, a thick band of connective tissues that run along the bottom of the foot. This ailment primarily affects the sole of the foot, causing discomfort and distress to patients of various age groups. The hallmark symptoms of plantar fasciitis include sharp or stabbing heel pain, often experienced during the first steps taken in the morning or after prolonged periods of rest. The pain can also intensify after standing or walking for a long time. The diagnosis of the illness typically involves a thorough clinical history review and a physical examination by a healthcare professional. They may inquire about the patient's symptoms, activity levels, and footwear choices. Physical assessment could involve checking for tenderness in the affected area and evaluating the range of motion of the foot and ankle. Imaging studies, like X-rays or ultrasound, may be utilized to rule out various other possible causes of heel pain.
The increasing prevalence of biomechanical abnormalities in the feet, legs, or gait that can lead to an unequal distribution of weight and stress on the connective tissues is primarily driving the plantar fasciitis market. In addition to this, the inflating utilization of effective interventions, such as orthotic devices, non-steroidal anti-inflammatory drugs (NSAIDs), physical therapy, and corticosteroid injections, for the purpose of managing symptoms and preventing further aggravation, is creating a positive outlook for the market. Moreover, the widespread adoption of stretching exercises and specialized footwear, as they contribute to the alleviation of pain, improvement of foot function, and restoration of mobility in individuals suffering from the illness, is also propelling the market growth. Apart from this, the rising usage of shockwave therapy, since it involves the application of acoustic waves to stimulate healing processes and reduce inflammation in the affected area, thereby promoting overall patient well-being, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of regenerative medicine approaches, which encompass techniques like platelet-rich plasma (PRP) injections to harness the body's healing mechanisms and accelerate tissue repair, is expected to drive the plantar fasciitis market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the plantar fasciitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for plantar fasciitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the plantar fasciitis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the plantar fasciitis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the plantar fasciitis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current plantar fasciitis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the plantar fasciitis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the plantar fasciitis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the plantar fasciitis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of plantar fasciitis across the seven major markets?
What is the number of prevalent cases (2018-2034) of plantar fasciitis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of plantar fasciitis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with plantar fasciitis across the seven major markets?
What is the size of the plantar fasciitis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of plantar fasciitis?
What will be the growth rate of patients across the seven major markets?
Plantar Fasciitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for plantar fasciitis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the plantar fasciitis market?
What are the key regulatory events related to the plantar fasciitis market?
What is the structure of clinical trial landscape by status related to the plantar fasciitis market?
What is the structure of clinical trial landscape by phase related to the plantar fasciitis market?
What is the structure of clinical trial landscape by route of administration related to the plantar fasciitis market?
The plantar fasciitis market has been comprehensively analyzed in IMARC's new report titled "Plantar Fasciitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Plantar fasciitis refers to a common condition that involves inflammation and irritation of the plantar fascia, a thick band of connective tissues that run along the bottom of the foot. This ailment primarily affects the sole of the foot, causing discomfort and distress to patients of various age groups. The hallmark symptoms of plantar fasciitis include sharp or stabbing heel pain, often experienced during the first steps taken in the morning or after prolonged periods of rest. The pain can also intensify after standing or walking for a long time. The diagnosis of the illness typically involves a thorough clinical history review and a physical examination by a healthcare professional. They may inquire about the patient's symptoms, activity levels, and footwear choices. Physical assessment could involve checking for tenderness in the affected area and evaluating the range of motion of the foot and ankle. Imaging studies, like X-rays or ultrasound, may be utilized to rule out various other possible causes of heel pain.
The increasing prevalence of biomechanical abnormalities in the feet, legs, or gait that can lead to an unequal distribution of weight and stress on the connective tissues is primarily driving the plantar fasciitis market. In addition to this, the inflating utilization of effective interventions, such as orthotic devices, non-steroidal anti-inflammatory drugs (NSAIDs), physical therapy, and corticosteroid injections, for the purpose of managing symptoms and preventing further aggravation, is creating a positive outlook for the market. Moreover, the widespread adoption of stretching exercises and specialized footwear, as they contribute to the alleviation of pain, improvement of foot function, and restoration of mobility in individuals suffering from the illness, is also propelling the market growth. Apart from this, the rising usage of shockwave therapy, since it involves the application of acoustic waves to stimulate healing processes and reduce inflammation in the affected area, thereby promoting overall patient well-being, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of regenerative medicine approaches, which encompass techniques like platelet-rich plasma (PRP) injections to harness the body's healing mechanisms and accelerate tissue repair, is expected to drive the plantar fasciitis market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the plantar fasciitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for plantar fasciitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the plantar fasciitis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the plantar fasciitis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the plantar fasciitis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current plantar fasciitis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the plantar fasciitis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the plantar fasciitis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the plantar fasciitis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of plantar fasciitis across the seven major markets?
What is the number of prevalent cases (2018-2034) of plantar fasciitis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of plantar fasciitis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with plantar fasciitis across the seven major markets?
What is the size of the plantar fasciitis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of plantar fasciitis?
What will be the growth rate of patients across the seven major markets?
Plantar Fasciitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for plantar fasciitis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the plantar fasciitis market?
What are the key regulatory events related to the plantar fasciitis market?
What is the structure of clinical trial landscape by status related to the plantar fasciitis market?
What is the structure of clinical trial landscape by phase related to the plantar fasciitis market?
What is the structure of clinical trial landscape by route of administration related to the plantar fasciitis market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 PLANTAR FASCIITIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 PLANTAR FASCIITIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 PLANTAR FASCIITIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 PLANTAR FASCIITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 PLANTAR FASCIITIS - UNMET NEEDS
10 PLANTAR FASCIITIS - KEY ENDPOINTS OF TREATMENT
11 PLANTAR FASCIITIS - MARKETED PRODUCTS
11.1 List of Plantar Fasciitis Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 PLANTAR FASCIITIS - PIPELINE DRUGS
12.1 List of Plantar Fasciitis Pipeline Drugs Across the Top 7 Markets
12.1.1 AmnioFix - MiMedx
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13 PLANTAR FASCIITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 PLANTAR FASCIITIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 PLANTAR FASCIITIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Plantar Fasciitis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Plantar Fasciitis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Plantar Fasciitis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Plantar Fasciitis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Plantar Fasciitis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Plantar Fasciitis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Plantar Fasciitis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Plantar Fasciitis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Plantar Fasciitis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Plantar Fasciitis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Plantar Fasciitis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Plantar Fasciitis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Plantar Fasciitis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Plantar Fasciitis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Plantar Fasciitis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Plantar Fasciitis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Plantar Fasciitis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Plantar Fasciitis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Plantar Fasciitis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Plantar Fasciitis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Plantar Fasciitis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Plantar Fasciitis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Plantar Fasciitis - Access and Reimbursement Overview
16 PLANTAR FASCIITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 PLANTAR FASCIITIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 PLANTAR FASCIITIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 PLANTAR FASCIITIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 PLANTAR FASCIITIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 PLANTAR FASCIITIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 PLANTAR FASCIITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 PLANTAR FASCIITIS - UNMET NEEDS
10 PLANTAR FASCIITIS - KEY ENDPOINTS OF TREATMENT
11 PLANTAR FASCIITIS - MARKETED PRODUCTS
11.1 List of Plantar Fasciitis Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 PLANTAR FASCIITIS - PIPELINE DRUGS
12.1 List of Plantar Fasciitis Pipeline Drugs Across the Top 7 Markets
12.1.1 AmnioFix - MiMedx
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13 PLANTAR FASCIITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 PLANTAR FASCIITIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 PLANTAR FASCIITIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Plantar Fasciitis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Plantar Fasciitis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Plantar Fasciitis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Plantar Fasciitis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Plantar Fasciitis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Plantar Fasciitis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Plantar Fasciitis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Plantar Fasciitis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Plantar Fasciitis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Plantar Fasciitis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Plantar Fasciitis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Plantar Fasciitis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Plantar Fasciitis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Plantar Fasciitis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Plantar Fasciitis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Plantar Fasciitis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Plantar Fasciitis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Plantar Fasciitis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Plantar Fasciitis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Plantar Fasciitis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Plantar Fasciitis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Plantar Fasciitis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Plantar Fasciitis - Access and Reimbursement Overview
16 PLANTAR FASCIITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 PLANTAR FASCIITIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 PLANTAR FASCIITIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
